Back to top
April
11
2017

Genzyme CEO Steps Down as Dupixent is Approved

David Meeker, Sanfoi’s EVP and CEO of the Genzyme unit, will step down in June. The news came right after Sanofi and partner Regeneron gained approval for Dupixent, one of the biggest new drug of the year. Meeker was supposed to oversee the rollout of that drug, which is expected peak sales of above $3 billion. Now that responsibility will fall on his successor, Bill Sibold, Sanofi Genzyme’s head of multiple sclerosis, oncology and immunology. Sibold has been involved in the Dupixent project, along with the potential rollout of rheumatoid arthritis med sarilumab. In July 2015, Sanofi CEO Olivier Brandicourt, who just took over that February, put Sanofi’s specialty drugs, including oncology, under Genzyme. Then, he revamped the French drugmaker’s top management team to fit a “strategic roadmap”, and diabetes and cardiovascular chief Pascal Witz departed in that shakeup. FiercePharma

"Every science begins as philosophy and ends as art." Will Durant,